1 Title: Effectiveness of an Impella versus intra-aortic balloon pump in patients who received 2 extracorporeal membrane oxygenation

3

Authors: Yuji Nishimoto¹; Hiroyuki Ohbe²; Jun Nakata³; Toru Takiguchi⁴; Mikio Nakajima^{2,5};
Yusuke Sasabuchi⁶; Toshiaki Isogai^{2,7}; Hiroki Matsui²; Yukihito Sato⁸; Tetsuya Watanabe¹; Takahisa
Yamada¹; Masatake Fukunami¹; Hideo Yasunaga².

7

Affiliations: ¹Division of Cardiology, Osaka General Medical Center, Osaka, Japan. ²Department of 8 9 Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokvo. Japan. ³Division of Cardiovascular Intensive Care, Nippon Medical School, Tokyo, Japan. 10⁴Department of Emergency and Critical Care Medicine, Nippon Medical School, Tokyo, Japan. 11 12⁵Emergency and Critical Care Center, Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan. ⁶Department of Real-world Evidence, Graduate School of Medicine, The University of Tokyo, Tokyo, 13Japan. ⁷Department of Cardiology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan. 14 ⁸Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, 15Japan. 16

17

18 Address for correspondence: Hiroyuki Ohbe

Department of Clinical Epidemiology and Health Economics, School of Public Health, The
University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 1130033, Japan

21 TEL: +81-3-5841-1887 FAX: +81-3-5841-1888 E-mail: hohbey@gmail.com

- 22
- 23
- 24
- 25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1

2 Abstract

Background: Previous studies have suggested that left ventricular (LV) unloading with an intra-aortic balloon pump (IABP) or percutaneous ventricular assist device (Impella) in combination with extracorporeal membrane oxygenation (ECMO) is associated with lower mortality; however, it is unclear which is better. This study aimed to evaluate the effectiveness of LV unloading with an Impella versus IABP on in-hospital mortality and other clinical outcomes.

Methods: Using the Japanese Diagnosis Procedure Combination database from September 28, 2016, to March 31, 2022, we identified inpatients who received an Impella or IABP in combination with ECMO (ECPella or ECMO+IABP group, respectively). The primary outcome was in-hospital mortality and the secondary outcomes were the length of hospital stay, length of ECMO, total hospitalization cost, and complications. Propensity score matching was performed to compare the outcomes between the groups.

Results: Of 14,525 eligible patients, 603 (4.2%) received ECPella and 13,922 (96%) received ECMO+IABP. After propensity score matching, there was no significant difference in in-hospital mortality between the two groups (58.9% versus 56.6%; risk difference, 2.3%; 95% confidence interval, -3.9% to 8.5%). The ECPella group had a longer hospital stay, higher total hospitalization cost, and more frequent major bleeding, vascular complications, and renal replacement therapy during hospitalization than the ECMO+IABP group.

20 **Conclusions:** This nationwide inpatient database study showed that ECPella was not associated with 21 a survival benefit but was associated with a longer hospital stay, higher total hospitalization cost, and 22 more complications than ECMO+IABP.

23

Keywords: cardiogenic shock; mechanical circulatory support; extracorporeal membrane
 oxygenation; intra-aortic balloon pumping; heart-assist device

 $\mathbf{2}$

1

2 Introduction

Venoarterial extracorporeal membrane oxygenation (ECMO) provides strong hemodynamic support to patients with cardiogenic shock through retrograde aortic blood flow in addition to oxygenation;¹ however, even the latest evidence does not support a survival benefit with the routine use of ECMO in patients with cardiogenic shock.^{2,3} Potential reasons may include bleeding complications, peripheral vascular ischemia, pulmonary edema, and myocardial ischemia induced by an increased left ventricular (LV) afterload due to a strong retrograde aortic blood flow.¹

9 Previous studies have suggested that LV unloading with an intra-aortic balloon pump (IABP) or percutaneous ventricular assist device (Impella) in combination with ECMO is associated 10with a lower mortality.^{4–8} Those studies primarily focused on the effectiveness of LV unloading with 11 12an IABP or Impella, using patients who received ECMO alone as controls. The IABP reduces the LV afterload and provides indirect LV unloading through a negative systolic pressure in the descending 13aorta.⁹ whereas the Impella can directly decrease the LV overload and restore the pulmonary flow in 14 patients with ECMO who present with severe LV dysfunction.¹⁰ No randomized controlled trial 15compared the outcomes of using the Impella versus IABP in combination with ECMO. A recent 1617meta-analysis of seven small-scale observational studies showed no survival benefit of ECPella as compared to ECMO+IABP; however, those studies had a high heterogeneity and the results of the 18 meta-analysis were underpowered to assess the comparative effectiveness.¹¹ It remains unclear 1920whether differences in the device characteristics between the IABP and Impella affect the clinical 21outcomes in patients with ECMO who require LV unloading. Therefore, the present study aimed to evaluate the effectiveness of LV unloading with an Impella versus IABP on the in-hospital mortality 2223and other clinical outcomes, using a nationwide inpatient database in Japan.

24

25 Methods

1 Design and Ethical statement

This was a retrospective cohort study using an inpatient administrative database, and the study conformed to the RECORD reporting guidelines.¹² This study was conducted in accordance with the amended Declaration of Helsinki and was approved by the Institutional Review Board of The University of Tokyo (approval number, 3501-(5); 19 May 2021). Because the data were anonymous, the Institutional Review Board waived the requirement for informed consent.

 $\overline{7}$

8 Data source

9 We used the Japanese Diagnosis Procedure Combination inpatient database, which contained administrative claims data and discharge abstracts from more than 1,500 acute care hospitals and 10covers approximately 90% of all tertiary emergency hospitals in Japan.¹³ The database includes the 11 following patient-level data for all hospitalizations: age, sex, diagnoses (main diagnosis, 1213admission-precipitating diagnosis, resource-consuming diagnosis, second-most most resource-consuming diagnosis, comorbidities present at admission, and complications arising after 14admission) recorded with the International Classification of Diseases, 10th Revision (ICD-10) codes, 15daily procedures recorded using Japanese medical procedure codes, daily drug administration, and 16discharge status.¹³ A previous validation study showed that the specificity of the recorded diagnoses 17in the database exceeded 96%, the sensitivity of the diagnoses ranged from 50% to 80%, and the 18 specificity and sensitivity of the procedures both exceeded 90%.¹⁴ 19

20

21 Study population

We identified all patients who received ECMO during hospitalization from September 28, 2016, to March 31, 2022. September 28, 2016, was the date when the Impella was approved for reimbursement under the national health insurance in Japan. We excluded patients aged <18 years and those who had received neither an Impella nor IABP within 2 days before or after the ECMO

1 initiation. All patients were followed up until they died or were discharged from the hospital.

 $\mathbf{2}$

3 Treatment groups

Patients who received an Impella within 2 days before or after the ECMO initiation were defined as the ECMO+Impella (ECPella) group. Patients who received IABP within 2 days before or after the ECMO initiation were defined as the ECMO+IABP group. Patients who received both an Impella and IABP within 2 days before or after the ECMO initiation were assigned to the group with the later initiation date of the Impella or IABP, or defined as the ECPella group if the Impella or IABP was initiated on the same day.

10

11 Outcomes

12The primary outcome was in-hospital mortality. The secondary outcomes were the length of hospital stay, length of ECMO, total hospitalization cost, and complications including major bleeding, an 13ischemic stroke, vascular complications, and renal replacement therapy during hospitalization. Major 14bleeding was defined as the presence of either intracranial bleeding, intraspinal bleeding, pericardial 15hematomas, intra-abdominal or retroperitoneal hematomas, intra-articular bleeding, intraocular 1617bleeding, or compartment syndrome, which was in accordance with the International Society of Thrombosis and Haemostasis definition.¹⁵ Ischemic stroke was defined as the presence of cerebral 18 infarction or transient ischemic attack. Vascular complications were defined as an injury to a blood 1920vessel, noncoronary artery dissection, acquired arteriovenous fistula, acute limb thrombosis, and hemorrhage and/or hematoma following a circulatory system procedure.¹⁶ Those outcomes are 2122defined by the ICD-10 codes listed in **Supplemental Table S1**.

23

24 Covariates

25 The covariates were the fiscal year upon admission, age, sex, smoking history, body mass index upon

 $\mathbf{5}$

admission, Japan Coma Scale upon admission,¹⁷ Charlson comorbidity index score, comorbidity of 1 $\mathbf{2}$ peripheral vascular diseases, physical function measured by the Barthel index score upon admission,¹⁸ cognitive function before admission, home medical care before admission, place before 3 admission, ambulance use, primary diagnoses upon admission, extracorporeal cardiopulmonary 4 resuscitation (ECPR), interventions (percutaneous coronary intervention, coronary artery bypass $\mathbf{5}$ grafting, surgical valve procedures, or percutaneous valve procedures) before ECMO initiation, 6 7 organ failure support on the day of the ECMO initiation other than ECMO and mechanical ventilation.¹⁹ and hospital characteristics (teaching hospital, tertiary emergency hospital, and annual 8 9 hospital volume of ECMO). The primary diagnosis upon admission was defined when it appeared as a main diagnosis, admission-precipitating diagnosis, most resource-consuming diagnosis, or second 10most resource-consuming diagnosis¹³, and is defined by the ICD-10 codes listed in **Supplemental** 11 12Table S1. ECPR was defined as receiving chest compressions on the same day of the ECMO initiation. 13

14

15 Statistical analysis

We performed a propensity score-matching analysis to compare the outcomes between the ECPella 16and ECMO+IABP groups.²⁰ A multivariable logistic regression model using all the covariates listed 17in **Table 1** was employed to compute the propensity scores for the patients in the ECPella group. 18 19Then, we performed a one-to-one nearest-neighbor matching that randomly selected a patient from 20the treatment group and subsequently paired that patient with the patient in the control group with the closest propensity score.²¹ In the present study, each time a patient in the ECPella group was 21identified, the one-to-one nearest-neighbor matching without replacement was performed for the 2223estimated propensity scores using a caliper width set at 20% of the standard deviation of the propensity scores in the patients in the ECMO+IABP group for the exact same calendar year and 24month.²⁰ To assess the performance of the matching, the covariates were compared using 25

standardized differences, with absolute standardized differences of $\leq 10\%$ considered to denote negligible imbalances between the two groups.²² After the propensity score matching, the primary and secondary outcomes for the two groups were assessed through a generalized linear model accompanied by cluster-robust standard errors with hospitals as the clusters. Differences and their 95% confidence intervals were calculated with generalized linear models using the identity link function, irrespective of the outcome types. For the 60-day in-hospital mortality, we also generated Kaplan–Meier curves and performed log-rank tests in the matched cohort.

8 All analyses were performed using STATA/SE 17.0 software (StataCorp). Continuous 9 variables are presented as the mean and standard deviation, and categorical variables are presented as 10 the number and percentage. We considered all reported p-values as two-sided and a p<0.05 as 11 statistically significant.

12

13 Sensitivity analysis

We performed two sensitivity analyses. First, we performed an overlap weighting analysis.²³ The overlap weighting analysis emphasized the target population with the most overlap in the observed characteristics between two groups. The differences and their 95% confidence intervals were calculated with weighted generalized linear models to compare the outcomes. Second, patients who received ECPR may have had a substantially different clinical course in terms of post-cardiac arrest syndrome and the prognosis as compared to those with cardiogenic shock who did not receive ECPR. Therefore, we performed sensitivity analyses excluding the patients who received ECPR.

21

22 **Results**

23 Patient characteristics and outcomes

During the study period, we identified 14,525 eligible patients from 661 hospitals (**Figure 1**). Of those, 603 (4.2%) were identified as the ECPella group, and 13,922 (96%) as the ECMO+IABP

1 group. Of the overall 661 hospitals, Impella was used in 155 (23%).

Table 1 shows the patient characteristics before and after propensity score matching. In the $\mathbf{2}$ overall cohort, the mean age was 65 years, and 76% were men. Before the propensity score matching, 3 the patients in the ECPella group tended to be younger, had a poor physical and cognitive function 4 upon admission, were transferred from another hospital, had cardiomyopathy, received blood $\mathbf{5}$ 6 transfusions and dobutamine, and were admitted to a tertiary emergency hospital with a high annual hospital volume of ECMO. In contrast, the patients in the ECMO+IABP group tended to have poor $\overline{7}$ 8 consciousness, were admitted from home, had a cardiac arrest and ventricular tachycardia or 9 fibrillation, and required ECPR, dopamine, and adrenaline. One-to-one propensity score matching created 603 matched pairs. The distributions of the propensity scores before and after the matching 10are shown in Supplementary Figures S1 and S2. After the propensity score matching, the patient 11 12characteristics were well-balanced between the two groups (Table 1).

Table 2 shows the outcomes before and after propensity score matching. The crude 13in-hospital mortality was 58.9% in the ECPella group and 65.6% in the ECMO+IABP group. After 14propensity score matching, there was no significant difference in in-hospital mortality between the 15ECPella and ECMO+IABP groups (58.9% versus 56.6%; risk difference, 2.3%; 95% confidence 1617interval, -3.9% to 8.5%). A Kaplan-Meier analysis with the log-rank test showed no significant difference in the 60-day in-hospital mortality between the two groups (P value = 0.114) (Figure 2). 18 19The length of hospital stay was significantly longer in the ECPella group (mean 42.8 days versus 2033.7 days; risk difference, 9.1 days; 95% confidence interval, 2.6 to 15.6 days). The total 21hospitalization cost was also significantly higher in the ECPella group than in the ECMO+IABP group (12,573,000 yen versus 6,857,000 yen; risk differences, 5,716,000 yen; 95% confidence 2223interval, 4,439,000 yen to 6,993,000 yen). Complications more frequently occurred in the ECPella group than in the ECMO+IABP group, including major bleeding (4.0% versus 2.0%; risk difference, 242.0%; 95% confidence interval, 0.007% to 4.0%), vascular complications (4.1% versus 2.2%; risk 25

difference, 2.0%; 95% confidence interval, 0.04% to 3.9%), and renal replacement therapy during hospitalization (50.6% versus 41.1%; risk difference, 9.5%; 95% confidence interval, 3.0% to 15.9%). There were no significant differences in the other secondary outcomes including the length of ECMO (mean 3.9 days versus 3.3 days; risk difference, 0.6 days; 95% confidence interval, -0.8 to 2.0 days), and ischemic strokes (4.1% versus 4.1%; risk difference, 0.0%; 95% confidence interval, -2.1% to 2.1%). The results of the sensitivity analyses, using an overlap weighting analysis, showed similar results to those for the main analyses (**Table 3**).

8 **Supplementary Table S2** shows the results of the sensitivity analyses excluding patients 9 who received ECPR. After excluding 6,360 patients (44%) who received ECPR, there was no 10 significant difference in in-hospital mortality between the ECPella and ECMO+IABP groups (57.3% 11 versus 50.9%; risk difference, 6.5%; 95% confidence interval, -0.2% to 13.2%). The results of the 12 secondary outcomes were also consistent with the main analyses.

13

14 **Discussion**

To the best of our knowledge, this nationwide cohort study had the largest number of patients among the studies comparing ECPella versus ECMO+IABP. There was no significant difference in in-hospital mortality between the ECPella and ECMO+IABP groups. Meanwhile, ECPella was significantly associated with a longer hospital stay, higher total hospitalization cost, and more complications than ECMO+IABP.

The present study found no survival benefit of ECPella as compared to ECMO+IABP. This was consistent with the results of the previous studies.^{8,11} One of those studies, from the Extracorporeal Life Support Organization registry, showed a considerably higher proportion of Impella use in combination with ECMO (33% versus 4.2%).⁸ The previous study performed a propensity score-matching analysis and concluded ECPella as compared to ECMO+IABP was associated with a similar survival in the 560 matched pairs.⁸ Randomized controlled trials comparing

the LV unloading strategies are certainly needed to reach any conclusions. To investigate the 1 $\mathbf{2}$ comparative effectiveness of Impella or IABP use in combination with ECMO, future studies may need to consider the following. First, the etiology of cardiogenic shock may be a key issue. 3 Underlying diseases with severe impairment of the LV contractility, such as fulminant myocarditis, 4 could receive a pathophysiological benefit from ECPella as a bridge to recovery;^{24,25} however, the $\mathbf{5}$ 6 current number of cases could not substantiate this subgroup analysis. Indeed, the present study $\overline{7}$ included only 140/1,206 (11.6%) patients with myocarditis. Second, the relationship between the 8 procedural volume (i.e., learning curves) and outcomes should also be considered. Data are scarce 9 for Impella, but the association between the procedural volume and outcomes has been shown for ECMO.²⁶ Hence, when involving data early after the approval of the Impella, as in the present study, 10the survival benefit of ECPella may be underestimated. Finally, early recognition of cardiogenic 11 12shock and its stabilization by an appropriate timing of mechanical circulatory support (MCS) device use may be more critical than that in which an MCS device is used.^{27,28} 13

In the present study, the total hospitalization cost was approximately 1.8 times higher in the 14ECPella group than in the ECMO+IABP group. This was partly because the cost of the Impella itself 15was considerably higher than that of an IABP or ECMO; it was approximately 17 times higher than 16an IABP and 7 times higher than ECMO, according to the national health reimbursement data in 17Japan.²⁹ Moreover, a longer hospital stay and more complications including major bleeding, vascular 18 19complications, and renal replacement therapy during hospitalization may have contributed to a 20higher total hospitalization cost. A recent study, using the nationwide inpatient database in Japan, that 21included patients who required MCS early after admission also showed higher medical costs for ECPella than ECMO+IABP, potentially due to more frequent blood transfusions, a longer duration of 22ventilator support, and a longer length of hospital stay.³⁰ In previous studies focusing on the temporal 23trends before and after the approval of the Impella, the hospitalization cost in the Impella era was 24higher than that in the pre-Impella era, especially in hospitals where the Impella was more frequently 25

used.^{31,32} Unplanned readmissions may be an important quality indicator in patients who received an
 Impella, with limited previous studies showing a high incidence of a 30-day readmission of more
 than 10%.³³ Unless the survival benefit and reduction in readmissions for ECPella as compared to
 ECMO+IABP is confirmed, clinicians should be cautious about the patient selection for Impella use
 in combination with ECMO for LV unloading.

6 Our results included some important clinical implications. First, the present study provided 7 no evidence of whether IABP or Impella was better for use in combination with ECMO, and 8 evidence of a longer hospital stay, higher total hospitalization cost, and more complications for 9 ECPella. This suggested that ECPella should be implemented in carefully selected patients. Second, 10 further studies are warranted to investigate the outcomes according to the etiology of the cardiogenic 11 shock, learning curves for Impella use, and readmissions in patients who received the Impella.

12The present study had several limitations. First, the decision on whether to use an IABP or Impella was at the individual clinician's discretion due to the nature of the present study using the 13observational database, which led to confounding by indication. We attempted to control for the 14measured confounding factors using the propensity score analyses; however, we were unable to 15control for any possible unmeasured variables, such as the vital signs, laboratory data, or LV function. 1617Second, the present study was unable to identify whether patients initially received IABP or Impella and then ECMO, or whether they initially received ECMO and then IABP or Impella for LV 18 19unloading. In addition, we defined 152 patients (40%) who received Impella and IABP in 20combination with ECMO on the same day as the ECPella group; however, some patients might have 21been downgraded from Impella to IABP due to Impella-related complications. Therefore, misclassifications may have led to a bias in our study. The order and combination of the MCS 2223devices depended on the changing severity of the cardiogenic shock, suggesting that it would be difficult to accurately categorize those complex processes even if additional information were 24available during hospitalization. Third, the present study was also unable to identify whether the 25

patients received an Impella 2.5, Impella CP, or Impella 5.0 in the ECPella group. Fourth, the incidence of complications in the present study was considerably lower than in the previous $\mathbf{2}$ studies.^{8,11} Given that the sensitivity of the diagnosis might have been low in our database, there was a possibility of underreporting complications. Finally, many patients in the present study received vasoactive drugs including dopamine and adrenaline. That might have delayed the MCS initiation $\mathbf{5}$ and caution should be taken in interpreting our results.

Conclusions

The present study using a nationwide inpatient administrative database showed that ECPella was not associated with any survival benefit but was associated with a longer hospital stay, higher total hospitalization cost, and more complications as compared to ECMO+IABP.

1	
2	
3	
4	Declarations
5	Ethics approval and consent to participate: This study was performed in accordance with the
6	amended Declaration of Helsinki, and the Institutional Review Board of The University of Tokyo
7	approved this study (approval number: 3501-(3); 25 December 2017).
8	
9	Consent for publication: The review board waived the requirement for informed consent because of
10	the anonymous nature of the data. No information describing the individual patients, hospitals, or
11	treating physicians was obtained.
12	
13	Availability of data and materials: The datasets analyzed during the current study are not publicly
14	available owing to contracts with the hospitals providing the data to the database.
15	
16	Competing interests: Drs. Nishimoto and Nakata received lecture fees from Abiomed Japan. All
17	other authors declare that they have no conflict of interest.
18	
19	Funding: This research was funded by grants from the Ministry of Health, Labour and Welfare,
20	Japan, grant numbers 23AA2003 and 22AA2003.
21	
22	Authors' contributions: Yuji Nishimoto: Conceptualization, Software, Formal analysis,
23	Investigation, Writing - Original Draft; Hiroyuki Ohbe: Conceptualization, Methodology, Software,
24	Formal analysis, Investigation, Writing - Review and Editing; Jun Nakata: Conceptualization,
25	Methodology, Investigation, Writing - Review and Editing, Supervision; Toru Takiguchi:

1 Conceptualization, Methodology, Investigation, Writing - Review and Editing, Supervision; Mikio $\mathbf{2}$ Nakajima: Conceptualization, Investigation, Writing - Review and Editing, Supervision; Yusuke 3 Sasabuchi: Conceptualization, Investigation, Writing - Review and Editing, Supervision; Toshiaki Isogai: Software, Formal analysis, Investigation, Data Curation; Hiroki Matsui: Software, Formal 4 analysis, Investigation, Data Curation; Yukihito Sato: Software, Investigation, Resources, $\mathbf{5}$ Supervision; Tetsuya Watanabe: Software, Investigation, Resources, Supervision; Takahisa 6 7 Yamada: Software, Investigation, Resources, Supervision; Masatake Fukunami: Software, 8 Investigation, Resources, Supervision; Hideo Yasunaga: Writing - Review and Editing, Supervision. 9 All authors read and approved the final manuscript.

10

Acknowledgments: We would like to express our gratitude to Mr. John Martin for his grammatical
 assistance.

- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- _ _
- 21
- 22
- 23
- 24
- 25

-	

- 2
- 3

4 **References**

Chieffo A, Dudek D, Hassager C, et al. Joint EAPCI/ACVC expert consensus document on
 percutaneous ventricular assist devices. *European Heart Journal Acute Cardiovascular Care*.
 2021;10:570–583.

Ostadal P, Rokyta R, Karasek J, et al. Extracorporeal Membrane Oxygenation in the
 Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial. *Circulation*.
 2023;147:454–464.

Thiele H, Zeymer U, Akin I, et al. Extracorporeal Life Support in Infarct-Related
 Cardiogenic Shock. *N Engl J Med.* 2023;389:1286–1297.

Russo JJ, Aleksova N, Pitcher I, et al. Left Ventricular Unloading During Extracorporeal
 Membrane Oxygenation in Patients With Cardiogenic Shock. *Journal of the American College of Cardiology*. 2019;73:654–662.

Schrage B, Becher PM, Bernhardt A, et al. Left Ventricular Unloading Is Associated With
 Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal
 Membrane Oxygenation: Results From an International, Multicenter Cohort Study. *Circulation*.
 2020;142:2095–2106.

Bhatia K, Jain V, Hendrickson MJ, et al. Meta-Analysis Comparing Venoarterial
Extracorporeal Membrane Oxygenation With or Without Impella in Patients With Cardiogenic
Shock. *Am J Cardiol*. 2022;181:94–101.

7. Thevathasan T, Kenny MA, Krause FJ, et al. Left-ventricular unloading in extracorporeal
cardiopulmonary resuscitation due to acute myocardial infarction - A multicenter study. *Resuscitation*. 2023;186:109775.

8. Grandin EW, Nunez JI, Willar B, et al. Mechanical Left Ventricular Unloading in Patients
 Undergoing Venoarterial Extracorporeal Membrane Oxygenation. *J Am Coll Cardiol.* 2022;79:1239–1250.

4 9. Lüsebrink E, Binzenhöfer L, Kellnar A, et al. Venting during venoarterial extracorporeal
5 membrane oxygenation. *Clin Res Cardiol*. 2023;112:464–505.

Eliet J, Gaudard P, Zeroual N, et al. Effect of Impella During Veno-Arterial Extracorporeal
Membrane Oxygenation on Pulmonary Artery Flow as Assessed by End-Tidal Carbon Dioxide. *ASAIO J.* 2018;64:502–507.

9 11. Gandhi KD, Moras EC, Niroula S, et al. Left Ventricular Unloading With Impella Versus
10 IABP in Patients With VA-ECMO: A Systematic Review and Meta-Analysis. *Am J Cardiol.*11 2023;208:53–59.

Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies Conducted using
 Observational Routinely-collected health Data (RECORD) statement. *PLoS Med.* 2015;12:e1001885.
 Yasunaga H. Real World Data in Japan: Chapter II The Diagnosis Procedure Combination

15 Database. ACE. 2019;1:76–79.

16 14. Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of
17 diagnoses, procedures, and laboratory data in Japanese administrative data. *J Epidemiol*.
18 2017:27:476–482.

19 15. Schulman S, Angerås U, Bergqvist D, et al. Definition of major bleeding in clinical
20 investigations of antihemostatic medicinal products in surgical patients. *J Thromb Haemost*.
21 2010;8:202–204.

16. Lemor A, Dabbagh MF, Cohen D, et al. Rates and impact of vascular complications in
mechanical circulatory support. *Catheter Cardiovasc Interv*. 2022;99:1702–1711.

17. Shigematsu K, Nakano H, Watanabe Y. The eye response test alone is sufficient to predict
stroke outcome--reintroduction of Japan Coma Scale: a cohort study. *BMJ Open*. 2013;3:e002736.

1 18. Mahoney FI, Barthel DW. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. *Md* 2 *State Med J.* 1965;14:61–65.

3 19. Ohbe H, Yamana H, Matsui H, Yasunaga H. Development and validation of a 4 procedure-based organ failure assessment model for patients in the intensive care unit: an 5 administrative database study. *Acute Med Surg.* 2021;8:e719.

Rosenbaum PR, Rubin DB. Constructing a Control Group Using Multivariate Matched
Sampling Methods That Incorporate the Propensity Score. *The American Statistician*. 1985;39:33–
38.

9 21. Austin PC. A critical appraisal of propensity-score matching in the medical literature
10 between 1996 and 2003. *Stat Med.* 2008;27:2037–2049.

Austin PC. Balance diagnostics for comparing the distribution of baseline covariates
between treatment groups in propensity-score matched samples. *Stat Med.* 2009;28:3083–3107.

Li F, Thomas LE, Li F. Addressing Extreme Propensity Scores via the Overlap Weights. *Am J Epidemiol.* 2019;188:250–257.

15 24. Tominaga Y, Toda K, Miyagawa S, et al. Total percutaneous biventricular assist device
16 implantation for fulminant myocarditis. *J Artif Organs*. 2021;24:254–257.

17 25. Kawamura T, Toda K, Yoshioka D, et al. Less Invasive Left Ventricular Unloading With
18 Impella May Improve the Clinical Outcomes of Fulminant Myocarditis. *ASAIO J.* 2023;69:561–568.

Becher PM, Goßling A, Schrage B, et al. Procedural volume and outcomes in patients
undergoing VA-ECMO support. *Crit Care*. 2020;24:291.

27. Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus statement on the
classification of cardiogenic shock: This document was endorsed by the American College of
Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine
(SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. *Catheter Cardiovasc Interv.*2019;ccd.28329.

28. Naidu SS, Baran DA, Jentzer JC, et al. SCAI SHOCK Stage Classification Expert
 Consensus Update: A Review and Incorporation of Validation Studies: This statement was endorsed
 by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP),
 American Heart Association (AHA), European Society of Cardiology (ESC) Association for Acute
 Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT),
 Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in
 December 2021. J Am Coll Cardiol. 2022;79:933–946.

8 29. Nishimoto Y, Inohara T, Kohsaka S, et al. Changing Trends in Mechanical Circulatory 9 Support Use and Outcomes in Patients Undergoing Percutaneous Coronary Interventions for Acute 10 Coronary Syndrome Complicated With Cardiogenic Shock: Insights From a Nationwide Registry 11 in Japan. *J Am Heart Assoc*. 2023;e031838.

30. Nitta M, Nakano S, Kaneko M, Fushimi K, Hibi K, Shimizu S. In-Hospital Mortality in
Patients With Cardiogenic Shock Requiring Veno-Arterial Extracorporeal Membrane Oxygenation
With Concomitant Use of Impella vs. Intra-Aortic Balloon Pump - A Retrospective Cohort Study
Using a Japanese Claims-Based Database. *Circ J*. 2024, doi: 10.1253/circj.CJ-23-0758.

Amin AP, Spertus JA, Curtis JP, et al. The Evolving Landscape of Impella Use in the
United States Among Patients Undergoing Percutaneous Coronary Intervention With Mechanical
Circulatory Support. *Circulation*. 2020;141:273–284.

32. Nishimoto Y, Ohbe H, Matsui H, et al. Trends in Mechanical Circulatory Support Use and
Outcomes of Patients With Cardiogenic Shock in Japan, 2010 to 2020 (from a Nationwide Inpatient
Database Study). *Am J Cardiol.* 2023;203:203–211.

- 33. Kuchtaruk AA, Sparrow RT, Azzalini L, et al. Unplanned readmissions after Impella
 mechanical circulatory support. *Int J Cardiol.* 2023;379:48–59.
- 24
- 25

1	
2	
3	
4	
5	Figure Legends
6	Figure 1. Patient flowchart
7	ECMO, extracorporeal membrane oxygenation; ECPella, combination of ECMO and Impella; IABP,
8	intra-aortic balloon pump.
9	
10	Figure 2. Kaplan–Meier curves for the 60-day in-hospital mortality
11	ECMO, extracorporeal membrane oxygenation; ECPella, combination of ECMO and Impella; IABP,
12	intra-aortic balloon pump.
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

- $\mathbf{2}$

Table 1. Patient characteristics

	Before matching			After matching		
	ECPella	ECMO+IABP		ECPella	ECMO+IABP	
	(n = 603)	(n = 13,922)	SMD	(<i>n</i> = 603)	(n = 603)	SMD
Fiscal year upon admission, n (%)						
2016	0 (0.0)	1,291 (9.3)	-45.2	0 (0.0)	0 (0.0)	0
2017	16 (2.7)	2,845 (20.4)	-57.9	16 (2.7)	13 (2.2)	3.2
2018	47 (7.8)	2,826 (20.3)	-36.6	47 (7.8)	49 (8.1)	-1.2
2019	130 (21.6)	2,516 (18.1)	8.8	130 (21.6)	131 (21.7)	-0.4
2020	168 (27.9)	2,363 (17.0)	26.3	168 (27.9)	167 (27.7)	0.4
2021	242 (40.1)	2,081 (14.9)	58.7	242 (40.1)	243 (40.3)	-0.3
Age, years, mean (SD)	63.1 (14.4)	65.2 (14.1)	-14.8	63.1 (14.4)	63.5 (15.5)	-2.7
Men, <i>n</i> (%)	461 (76.5)	10,642 (76.4)	0.0	461 (76.5)	461 (76.5)	0
Smoking history, <i>n</i> (%)						
Nonsmoker	239 (39.6)	5,670 (40.7)	-2.2	239 (39.6)	237 (39.3)	0.7
Current/past smoker	206 (34.2)	4,914 (35.3)	-2.4	206 (34.2)	208 (34.5)	-0.7
Unknown	158 (26.2)	3,338 (24.0)	5.1	158 (26.2)	158 (26.2)	0
Body mass index upon admission, kg/m ² , n						
(%) <18.5	<i>1</i> 3 (7 1)	855 (6 1)	4.0	13 (7 1)	37 (6 1)	4.0
18.5 24.0	43(7.1)	6 601 (47 4)	4.0 0.3	43(7.1)	37 (0.1)	4.0 7 3
25.0. 20.0	137(22.7)	3,344(24,0)	9.5 3.1	137(22.1)	132(21.9)	2.0
>30.0	157 (22.7)	1,062 (7,6)	-3.1	157 (22.7)	30 (6 5)	2.0
<u>2</u> 50.0	40(7.0)	1,002(7.0)	12.1	40(7.0)	59 (0.5) 50 (0.8)	4.5
$\frac{1}{10000000000000000000000000000000000$	03 (10.4)	2,000 (14.8)	-13.1	03 (10.4)	39 (9.8)	2.2
Japan Coma Scale upon admission, n (%)	210(514)	(152(442))	145	210(514)	282(46.0)	0.0
0 (alert)	310(31.4) 84(13.0)	0,155(44.2) 1 150(8 3)	14.5	310(31.4) 84(13.0)	283 (46.9)	9.0
1-3 (uzzy)	27 (4.5)	1,159 (8.3) 560 (4.0)	23	27 (4.5)	25(41)	-5.5
100-300 (coma)	27(4.3) 182(302)	6 050 (43 5)	-27.8	27(4.3) 182(302)	204 (33.8)	-7.8
Charlson comorbidity index score, mean (SD)	1.1 (1.2)	1.2 (1.3)	-2.4	1.1 (1.2)	1.3 (1.3)	-8.8
Comorbidity of peripheral vascular diseases, <i>n</i>	16 (2.7)	438 (3.1)	-2.9	16 (2.7)	16 (2.7)	0
$\binom{9}{1}$ Physical function upon admission n (%)						
Total/severe dependence (BL0-60)	409 (67 8)	8 630 (62 0)	123	409 (67 8)	402 (66 7)	25
Slight/moderate dependence (BL 61-99)	13 (2 2)	385 (2.8)	-3.9	13 (2 2)	16(27)	-3.2
Independent (BI – 100)	86 (14 3)	2 617 (18 8)	-12.2	86 (14-3)	77 (12.8)	1.4
Miceina	95 (15.8)	2,017(10.0) 2,290(16.4)	-1.9	95 (15.8)	108(17.9)	-5.8
Cognitive function before admission n (%)	<i>)5</i> (15.0)	2,290 (10.4)	1.9)5 (15.0)	100 (17.5)	5.0
No dementia	403 (66 8)	10 446 (75 0)	18 1	403 (66 8)	398 (66 0)	18
Mild domentie	403(00.0)	770 (5 5)	-10.1	403(00.0)	338 (00.0)	1.0
Moderate/severe demontin	31(3.1)	460 (3.4)	-1.7	21(3.1)	33(3.3)	-1.5
Missing	21(3.3)	409 (3.4) 2 227 (16 1)	21.2	21(3.3)	27 (4.0)	-0.7
Wissing	14ð (24.3) 5 (0.9)	2,237(10.1)	21.2 4.0	148 (24.3) 5 (0.9)	143(23.7) 10(1.7)	1.9 7 5
Place before admission, $n(\%)$	5 (0.8)	1/2(1.2)	-4.0	5 (0.8)	10(1.7)	-1.5
Frace before admission, $n(\%)$	470 /70 A	10 706 (01 5)	27.1	470 (70 A)	402 (01.0)	0.2
Home	4/3 (/8.4)	12,736 (91.5)	-37.1	4/3(/8.4)	493 (81.8)	-8.3

medRxiv preprint doi: https://doi.org/10.1101/20 preprint (which was not certified by peer rev	024.03.28.243050 riew) is the author	040; this version pos /funder, who has gr	sted March anted med	30, 2024. The copy Rxiv a license to di	right holder for this splay the preprint	s in
It is made avail	lable under a CC-	BY-NC-ND 4.0 Inter	rnational lic	ense.		10 5
Other hospitals	124 (20.6)	1,081 (7.8)	37.3	124 (20.6)	99 (16.4)	10.7
Nursing home	6 (1.0)	105 (0.8)	2.6	6 (1.0)	11 (1.8)	-7.0
Ambulance use, n (%)	474 (78.6)	10,512 (75.5)	7.4	474 (78.6)	487 (80.8)	-5.4
Primary diagnosis, n (%)						
Acute coronary syndrome	335 (55.6)	7,846 (56.4)	-1.6	335 (55.6)	341 (56.6)	-2.0
Cardiac arrest	94 (15.6)	3,570 (25.6)	-25.0	94 (15.6)	115 (19.1)	-9.2
Ventricular tachycardia or fibrillation	50 (8.3)	1,586 (11.4)	-10.4	50 (8.3)	49 (8.1)	0.6
Heart failure	85 (14.1)	1,545 (11.1)	9.0	85 (14.1)	93 (15.4)	-3.7
Valve disease	27 (4.5)	761 (5.5)	-4.5	27 (4.5)	22 (3.6)	4.2
Myocarditis	74 (12.3)	629 (4.5)	28.2	74 (12.3)	74 (12.3)	0
Cardiomyopathy	46 (7.6)	495 (3.6)	17.8	46 (7.6)	44 (7.3)	1.3
Aortic disease	13 (2.2)	193 (1.4)	5.8	13 (2.2)	10 (1.7)	3.6
Extracorporeal cardiopulmonary resuscitation, n (%)	139 (23.1)	6,221 (44.7)	-46.9	139 (23.1)	140 (23.2)	-0.4
Interventions before ECMO, n (%)	206 (50 7)	7 (1) (547)	7.0	20((50.7)	212(51.0)	2.2
Percutaneous coronary intervention	306 (50.7)	7,010 (54.7)	-7.9	306 (50.7)	313 (51.9)	-2.5
Coronary artery bypass grafting	34 (5.6)	804 (5.8)	-0.6	34 (5.6)	39 (6.5)	-3.5
Surgical valve procedures	22 (3.6)	439 (3.2)	2.7	22 (3.6)	17 (2.8)	4.7
Percutaneous valve procedures	4 (0.7)	219 (1.6)	-8.7	4 (0.7)	3 (0.5)	2.2
Organ failure supports on ECMO initiation, <i>n</i> (%)			•			• •
Red blood cell transfusion	449 (74.5)	8,647 (62.1)	26.8	449 (74.5)	443 (73.5)	2.3
Fresh frozen plasma transfusion	349 (57.9)	6,634 (47.7)	20.6	349 (57.9)	354 (58.7)	-1.7
Platelet transfusion	147 (24.4)	2,175 (15.6)	22.0	147 (24.4)	134 (22.2)	5.1
Dopamine	123 (20.4)	4,701 (33.8)	-30.4	123 (20.4)	117 (19.4)	2.5
Dobutamine	313 (51.9)	6,191 (44.5)	14.9	313 (51.9)	299 (49.6)	4.6
Noradrenaline	467 (77.4)	10,654 (76.5)	2.2	467 (77.4)	462 (76.6)	2.0
Adrenaline	314 (52.1)	9,802 (70.4)	-38.3	314 (52.1)	308 (51.1)	2.0
Vasopressin	39 (6.5)	982 (7.1)	-2.3	39 (6.5)	43 (7.1)	-2.6
Renal replacement therapy	124 (20.6)	2,596 (18.6)	4.8	124 (20.6)	121 (20.1)	1.2
Hospital characteristics						
Teaching hospital, <i>n</i> (%)	594 (98.5)	13,676 (98.2)	2.2	594 (98.5)	593 (98.3)	1.3
Tertiary emergency hospital, n (%)	443 (73.5)	8,802 (63.2)	22.2	443 (73.5)	429 (71.1)	5.2
Annual hospital volume of ECMO, mean (SD)	69.4 (28.1)	52.5 (30.9)	57.2	69.4 (28.1)	70.1 (33.3)	-2.4

BI, Barthel Index; ECMO, extracorporeal membrane oxygenation; ECPella, combination of ECMO and Impella; IABP, intra-aortic balloon pump; SD, standard deviation; SMD, standardized mean difference.

Table 2. Outcomes before and after propensity score matching

	Before matching		After matching			
	ECPella	ECMO+IABP	ECPella	ECMO+IABP	Risk difference	
	(<i>n</i> = 603)	(n = 13,922)	(n = 603)	(n = 603)	(95% CI)	P value
In-hospital mortality, <i>n</i> (%)	355 (58.9)	9,127 (65.6)	355 (58.9)	341 (56.6)	2.3 (-3.9, 8.5)	0.461
Length of hospital stay, days, mean (SD)	42.8 (60.0)	28.7 (42.8)	42.8 (60.0)	33.7 (42.0)	9.1 (2.6, 15.6)	0.006
Length of ECMO, days, mean (SD)	3.9 (7.5)	2.3 (8.3)	3.9 (7.5)	3.3 (13.3)	0.6 (-0.8, 2.0)	0.418
Total hospitalization cost, $\times 10^3$ yen, mean (SD)	12,573 (10,300)	5,679 (5,315)	12,573 (10,300)	6,857 (7,624)	5,716 (4,439, 6,993)	< 0.001
Complications, <i>n</i> (%)						
Major bleeding	24 (4.0)	277 (2.0)	24 (4.0)	12 (2.0)	2.0 (0.007, 4.0)	0.049
Ischemic stroke	25 (4.1)	451 (3.2)	25 (4.1)	25 (4.1)	0.0 (-2.1, 2.1)	1.000
Vascular complications	25 (4.1)	270 (1.9)	25 (4.1)	13 (2.2)	2.0 (0.04, 3.9)	0.046
Renal replacement therapy during hospitalization	305 (50.6)	5,430 (39.0)	305 (50.6)	248 (41.1)	9.5 (3.0, 15.9)	0.004

CI, confidence interval; ECMO, extracorporeal membrane oxygenation; ECPella, combination of ECMO and Impella; IABP, intra-aortic balloon pump; SD, standard deviation.

Table 3. Overlap weighting

_

	After IPTW			
	ECPella	ECMO+IABP	Risk difference (95% CI)	P value
In-hospital mortality, %	60.1	57.8	2.4 (-2.3, 7.0)	0.324
Length of hospital stay, days, mean (SD)	41.1 (56.7)	33.9 (48.8)	7.2 (2.1, 12.4)	0.006
Length of ECMO, days, mean (SD)	3.8 (7.2)	2.9 (12.2)	0.9 (0.06, 1.8)	0.035
Total hospitalization cost, $\times 10^3$ yen, mean (SD)	12,133 (9,472)	6,758 (7,014)	5,375 (4,310, 6,440)	< 0.001
Complications, %				
Major bleeding	3.9	2.5	1.5 (-0.2, 3.2)	0.091
Ischemic stroke	4.1	3.8	0.3 (-1.3, 1.9)	0.709
Vascular complications	4.1	2.4	1.7 (-0.2, 3.5)	0.078
Renal replacement therapy during hospitalization	49.8	40.5	9.3 (4.2, 14.5)	< 0.001

CI, confidence interval; ECMO, extracorporeal membrane oxygenation; ECPella, combination of ECMO and Impella; IABP, intra-aortic balloon pump; SD, standard deviation.

31,486 patients who received ECMO during hospitalization from September 28, 2016 to March 31, 2022

16,961 patients were excluded:
977 patients under 18 years old
15,984 patients who had received neither Impella nor IABP within 2 days before or after the ECMO initiation

14,525 patients remained

603 patients in the ECPella group

603 patients matched

603 patients matched

13,922 patients in the

ECMO+IABP group

